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To combat drug resistance, new chemical entities are urgently required for use in next
generation anti-malarial combinations. We report here the results of a medicinal chemistry
programme focused on an imidazopyridine series targeting the Plasmodium falciparum cyclic
GMP-dependent protein kinase (PfPKG). The most potent compound (ML10) has an IC50 of
160 pM in a PfPKG kinase assay and inhibits P. falciparum blood stage proliferation in vitro
with an EC50 of 2.1 nM. Oral dosing renders blood stage parasitaemia undetectable in vivo
using a P. falciparum SCID mouse model. The series targets both merozoite egress and
erythrocyte invasion, but crucially, also blocks transmission of mature P. falciparum game-
tocytes to Anopheles stephensi mosquitoes. A co-crystal structure of PvPKG bound to ML10,
reveals intimate molecular contacts that explain the high levels of potency and selectivity we
have measured. The properties of this series warrant consideration for further development
to produce an antimalarial drug.
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Malaria, caused by species of the protozoan Plasmodium,remains the most serious parasitic disease in humans.Around 212 million cases of malaria and approximately
429,000 deaths occurred in 20151. Prolonged parasite clearance
times, and increasing frequencies of treatment failures following
treatment of malaria with artemisinin combination therapies are
now regularly reported in parts of Southeast Asia2–5. This has led
to concerns about the emergence and spread of resistance to these
relatively new medicines, which are the mainstay globally for the
treatment of malaria caused by Plasmodium falciparum6, 7. New
non-endoperoxide drugs are considered essential for inclusion as
components of novel combination treatments, should the arte-
misinin derivatives eventually fail.
PKG is a cyclic GMP (cGMP)-activated serine/threonine pro-
tein kinase that regulates numerous functions in diverse organ-
isms. There is a single PKG gene in malaria parasites and the
P. falciparum enzyme, encoded by PfPKG (PlasmoDB Gene ID
PF3D7_1436600), has previously been shown to have properties
distinct from human orthologes8. Selective inhibitors of PKG
from the related parasite Eimeria, are thought to interact with a
small hydrophobic pocket adjoining the ATP-binding site. Access
to this pocket is possible due to the presence of a small (threo-
nine) gatekeeper residue in PKG from both Eimeria and Plas-
modium (T618 in PfPKG)9, 10. All mammalian PKGs and most
serine/threonine kinases have a large gatekeeper residue11 pre-
venting access to the pocket and making them insensitive to the
PKG inhibitors mentioned above and likely explaining the high
levels of selectivity observed9, 10. These PKG inhibitors also block
the development of a number of Plasmodium life cycle stages12–18
and we have used a chemical genetic approach that exploits the
small gatekeeper residue in PfPKG to generate an inhibitor-
resistant P. falciparum transgenic line (T618Q), to demonstrate
that this enzyme plays an essential role in blood stage replication
in the human host as well as gametogenesis and ookinete motility
in the mosquito vector. The compounds block P. falciparum
blood stage replication by preventing not only schizont rupture
and merozoite egress17, 19, but also merozoite invasion of red
blood cells12. Prevention of egress is in part due to a downstream
block in the PKG-dependent function of the protease PfSUB120
through the inhibition of its release from exonemes, and the
subsequent release of microneme proteins required for ery-
throcyte invasion19. Inhibition of PfPKG activity also blocks
calcium mobilization that is required for merozoite egress and
invasion and which is thought to be mediated through phos-
phoinositide metabolism13. Using a phosphoproteome analysis
we recently identiﬁed ~ 70 P. falciparum proteins expressed in
mature schizonts that are phosphorylated in a PKG-dependent
manner. These proteins are involved in a wide range of cellular
processes including cell signaling, ion/protein transport, chro-
matin remodeling, and actomyosin motor function12.
Here, we show that our newly synthesized imidazopyridine
PKG inhibitors have high potency and selectivity against
P. falciparum blood stage proliferation in vitro and in vivo, and
that they block transmission of gametocytes to Anopheles mos-
quitoes. We also present co-crystal structures of P. vivax PKG
with the inhibitors, which reveal the interactions underpinning
the high degree of selectivity we have observed.
Results
Highly potent PKG inhibitors block blood stage proliferation.
Using the Merck imidazopyridine, compound 2 (ML1) (4-[7-
[(dimethylamino)methyl]-2-(4-ﬂuorophenyl)imidazo[1,2-a]pyr-
idine-3-yl]pyrimidin-2-amine), developed to treat Eimeria infec-
tion9 as the chemistry starting point, we synthesized new analogs.
These were ﬁrst tested for their ability to inhibit the kinase
activity of recombinant PfPKG using a microﬂuidic mobility shift
assay (see Methods). The best IC50 values obtained were <200 pM
(Table 1). Selected compounds were also tested in the kinase assay
against a recombinant PfPKG mutant harbouring a T618Q sub-
stitution to investigate the importance of the gatekeeper pocket in
the inhibitory mechanism. This mutant kinase exhibited a
reduced sensitivity to many of the compounds of between 500
and >100,000-fold (Table 1 and Supplementary Fig. 1), empha-
sizing that this rare structural feature of PfPKG, is vital for
inhibitory activity.
The ability of the compounds to block P. falciparum asexual
blood stage growth in vitro was then determined using a growth
inhibition assay. Compounds had EC50 values ranging from ~
500 nM down to <5 nM (Table 1). Selected compounds were then
further assayed against the P. falciparum PKG gatekeeper mutant
line (T618Q)15 to determine whether PfPKG is their primary
target in the asexual blood stages. This line showed between a 10
to >1100-fold reduction in sensitivity to most compounds
(Table 1 and Supplementary Fig. 2) conﬁrming on-target activity.
Control drugs were tested in parallel to conﬁrm the changed
sensitivity of the gatekeeper mutant line was speciﬁc. Chloroquine
and artemisinin showed equivalent levels of inhibition of both
parasite lines, whereas the gatekeeper mutant line is pyrimetha-
mine resistant (as expected) due to the presence of the drug
selectable marker included in the plasmid construct used to
mediate allelic replacement (Supplementary Table 1). The
physical properties of compounds including stability in mouse
and human liver microsomes, membrane permeability and
lipophilicity were also measured (Supplementary Table 2; Meth-
ods) to inform the chemistry programme.
Starting with ML1, and working through several cycles of
design and synthesis (see Methods), we generated compounds
ML2-10 (Supplementary Fig. 3), which were selected for further
analysis (Table 1). ML10 is the most potent with an IC50 of ~ 160
pM against recombinant PfPKG and an EC50 value of ~ 2 nM
against P. falciparum blood stage parasite growth. The compound
also exhibited the largest difference in sensitivity between the
T618Q transgenic line and the WT 3D7 parasites (>1100-fold).
This demonstrates an extremely high degree of speciﬁcity for
PfPKG and indicates that any secondary parasite target is
inhibited only at high concentrations of the compound.
High in vivo efﬁcacy was obtained using the P. chabaudi
model. Compounds ML1, ML4 and ML10 were tested for in vivo
efﬁcacy in BALB/c mice infected with P. berghei using a Peters 4-
day test21 at a double daily dose of 25 mg/kg by oral gavage.
Reductions in blood stage parasitaemia measured after 4 days’
treatment compared to untreated controls were between 52.0 and
60.4% (Fig. 1a). Plasma samples were taken from satellite groups
of mice and all three compounds showed good levels of absorp-
tion at the 30 min time point, but plasma levels dropped mark-
edly over the next 30 min (Supplementary Fig. 4a) with half-lives
of around 1 h (ML1= 1.1 h, ML4= 1.0 h, and ML10= 0.8 h).
Given that PfPKG has a relatively narrow window of activity
spanning schizont rupture and merozoite invasion, and that
P. berghei develops asynchronously, it was reasoned that a higher
in vivo efﬁcacy might be achievable using the synchronous
P. chabaudi model, which would allow dosing to target the
window of PfPKG activity. A single daily oral dose (50 mg/kg) of
either ML1 or ML4 given to groups of ﬁve mice just prior to the
predicted onset of schizogony, led to a 67.9 and 56.5% reduction
in blood stage parasitaemia, respectively (Fig. 1b). We next
compared single and twice daily 50 mg/kg oral doses of ML10.
The twice daily dose (3 h apart) aimed to target the entire period
of schizont rupture and invasion with the intention of preventing
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any reinfection. The single dose experiment achieved a 60.9%
reduction in blood stage parasitaemia detected in blood ﬁlms
following 4 days’ treatment, whereas the double dose regimen
achieved a mean 97.8% reduction (Fig. 1c). Clearly, the second
dose was required to cover the entire period of schizont rupture
and re-invasion. There was no overt toxicity in either model.
Plasma samples were taken from satellite groups of mice given an
oral dose of 25 mg/kg or 50 mg/kg ML10. Supplementary
Figure 4b shows a comparison of the mean plasma levels of
ML10 measured at both doses. An almost threefold higher
concentration (10.4 μM) was measured at the 30-min time point
with the higher dose which was still around (8.4 μM) at 60 min.
Although this fell to less than 84 nM after 4 h, levels were still well
above the EC90 value obtained in the P. falciparum growth
inhibition assay. The half-life of ML10 in these experiments was
0.8 h (25 mg/kg) and 1.1 h (50 mg/kg).
Blood stage infection was cleared in a P. falciparum mouse
model. To further evaluate the efﬁcacy of ML10 it was tested in
the GSK P. falciparum mouse model (GSKPfalcHuMouse)
engrafted with human red blood cells22 by administering twice
daily doses of 50 or 100mg/kg via the oral route to two immu-
nodeﬁcient mice infected with P. falciparum 3D70087/N9 for
4 days. Both doses dramatically reduced parasitaemia (Fig. 2a),
with levels of ML10 in plasma far above the EC90 in vitro during
the 12-h period monitored (Supplementary Fig. 5). With the
higher dose, parasitaemia was not detectable at the end of the
treatment. The rate of parasite elimination was at least as good as
that obtained with meﬂoquine. The best estimate of potency was
AUCED90 <61.7 μg ml/h, with levels of compound orders of
magnitude higher than the EC90 in vitro. After one parasite cycle
of exposure, most remaining parasites in peripheral blood were at
the late schizont stage (Fig. 2b), suggesting that the process of
release of merozoites and invasion of erythrocytes are critical
steps of the P. falciparum cycle targeted by ML10. The improved
efﬁcacy in the GSKPfalcHuMouse model is probably not due to
sequence differences between PfPKG and the rodent malaria
parasite PKGs, because we previously showed that a transgenic
P. berghei line in which Pb PKG was replaced by PfPKG showed
equivalent sensitivity to the chemistry start point (ML1)23. It is
likely that the higher dose regimen and the resulting higher
plasma concentrations of compounds over time obtained in the
SCID experiment were responsible for the signiﬁcant activity
observed. The half-life values for ML10 in these experiments was
8.7 h (50 mg/kg) and 17 h (100 mg/kg). Importantly, the blood
stage of the P. falciparum life cycle is 48 h compared to 24 h with
the rodent malaria parasite species, which likely increases expo-
sure of the sensitive stages to the compound and contributes to
the increased efﬁcacy. To investigate the dynamics of parasite
killing, an in vitro parasite reduction rate (PRR) assay was carried
out24. A lag of about 24 h was observed, during which time the
effects of the compounds were reversible following wash-out.
However, rapid killing occurred after parasites had been exposed
to ML10 for more than 24 h (Fig. 2c). This killing proﬁle is
consistent with PfPKG inhibitors acting at the egress/invasion
stage as the starting parasite population in this assay is >80%
rings. Results are also indicative that inhibition of these cellular
processes is lethal and parasites cannot recover even if compound
is no longer present. Figure 2c shows the proﬁle of ML10 com-
pared to those of control antimalarial compounds assayed in the
same way.
The series blocks transmission of P. falciparum to mosquitoes.
We also tested the transmission-blocking effects of this series by
pre-incubating mature P. falciparum gametocytes (strain NF54)
for 24 h with ML1, ML4, and ML10 and then feeding them to
Anopheles stephensi mosquitoes using standard membrane feed-
ing assays (SMFA;25 to measure oocyst numbers at the various
concentrations). Potent transmission-blocking activity was
observed for the new compounds, with IC50 values for reduction
of the intensity of infection being 507.3, 61.6 and 41.3 nM,
respectively, (Fig. 3 and Supplementary Fig. 6). We have
Table 1 Compound potency in kinase and cell-based assays
Compound
name
IC50 WT (nM)
(n= )
IC50 T618Q
(nM)
(n= )
EC50 WT (nM)
(n= )
EC50 T618Q (nM)
(n= )
EC90 WT (nM)
(n= )
EC90 T618Q (nM)
(n= )
ML1 3.1 + /−0.22
(68)
8440 + /−1070
(14)
395.0 + /−21.9 (82) 5952 + /−594.7 (14) 696.8 + /−98 .9 (82) 20,715 + /−3209 (14)
ML2 1.71 + /−0.22
(2)
1713 + /−218.5
(2)
196.6 + /−13.4 (6) 140.2 + /−12.0 (3) 627.6 + /−125.8 (6) 955.7 + /−58.2 (3)
ML3 0.79 + /−0.15
(2)
842 + /−74.9
(2)
63.4 + /−3.7 (9) 195.1 + /−8.1 (3) 235.5 + /−18.7 (9) 278.7 + /−29.4 (3)
ML4 0.45 + /−0.04
(2)
231 + /−9.1
(2)
25.3 + /−1.7 (12) 106.7 + /−12.2 (3) 106.6 + /−13.4 (12) 185.8 + /−26.2 (3)
ML5 0.88 + /−0.04
(2)
>100,000
(4)
329.1 + /−3.5 (6) 12,735 + /−1519 (3) 445.2 + /−2.5 (6) 61,465 + /−1542 (3)
ML6 0.13 + /−0.02
(2)
52,500 + /−1000
(2)
102.3 + /−13.4 (6) 1855 + /−147.5 (3) 141.5 + /−12.2 (6) 3491 + /−822 (3)
ML7 4.34 + /−0.04
(2)
>100,000
(2)
488.9 + /−39.4 (6) 35,111 + /−2739 (3) 633.3 + /−15.8 (6) 60,663 + /−2931 (3)
ML8 0.79 + /−0.01
(2)
73,730
(4)
148.1 + /−10.6 (9) 5574 + /−474.1 (3) 181.6 + /−8.6 (9) 31,022 + /−2243 (3)
ML9 1.19 + /−0.07
(2)
>100,000
(2)
104.6 + /−5.3 (6) 6900 + /−922.1 (3) 158.1 + /−6.8 (6) 48,327 + /−1790 (3)
ML10 0.16 + /−0.01
(2)
29,540 + /−519
(2)
2.1 + /−0.2 (18) 2430 + /−413.3 (6) 4.50 + /−0.5 (18) 4612 + /−1549 (6)
Compounds were tested for their ability to inhibit the protein kinase activity of the full length 6His-tagged PfPKG recombinant protein (IC50). This was carried out using a microﬂuidic mobility shift assay,
which measures the separation of phosphorylated/non-phosphorylated forms of a ﬂuorescent peptide substrate to evaluate conversion. Hypoxanthine incorporation assays were then used to measure
the ability of the newly synthesized compounds to inhibit P. falciparum (3D7 and T618Q clonal lines) asexual blood stage growth in vitro (EC50 and EC90). Data are in nM ( + /− the s.e.m.). The number of
biological replicates (carried out in triplicate) is shown in brackets
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previously shown that PKG is essential for gametocyte activation
and transformation into gametes15, and propose that inhibition of
these events underlies the observed transmission-blocking activ-
ity. To conﬁrm the mechanism of action of ML10 in gametocytes,
we compared the ability of ML1 and ML10 to block rounding up
of P. falciparum wild-type (3D7) and gatekeeper mutant (T618Q)
stage V gametocytes. Both compounds blocked rounding up of
wild-type gametocytes, but the majority of T618Q gametocytes
were able to round up in the presence of both PKG inhibitors
showing that they are insensitive to the compounds and thereby
conﬁrming that the primary target of ML10 (and ML1 as pre-
viously shown15) is PKG in gametocytes as well as in blood stages
(Supplementary Fig. 7).
ML10 has little activity against human kinases and cell lines.
To assess the selectivity of ML10, it was tested against a panel of
80 human protein kinases (representing all the main families and
including 14 small gatekeeper kinases) and it showed a clean
proﬁle with only low levels of inhibitory activity when tested at
100 nM (>600× IC50 against recombinant PfPKG) (Supplemen-
tary Fig. 8). Although achieved through an independent experi-
mental approach, this result is consistent with the observed
>1100-fold difference in sensitivity between wild-type and gate-
keeper mutant parasites reﬂecting the exquisite speciﬁcity of this
compound for PfPKG. Of the panel of 80 human kinases, the
highest level of inhibition was obtained with human MLK3 (40%
at 100 nM). MLK3 has a very low overall similarity to PfPKG with
their kinase domains having only 22% identity. Human MLK3
has a large hydrophobic residue (methionine) in the gatekeeper
position, which would prevent access of the inhibitor to the
gatekeeper pocket and the IC50 for ML10 with MLK3 is >600-fold
higher than with PfPKG. The three MLK isoforms most similar to
MLK3 are MLK1, MLK2 and MLK4 and these also have bulky
hydrophobic gatekeeper residues. Compounds ML1-10 were
tested in cytotoxicity assays using HepG2 cells (derived from liver
hepatocellular carcinoma). ML10 and most of those tested had
EC50 values higher than the maximum dose tested (Supplemen-
tary Table 2). To provide additional safety data for ML10, it was
tested against three additional human cell lines at concentrations
between 0.001–10 µM (n= 6; CXR Biosciences Ltd; Supplemen-
tary Fig. 9) derived from lung carcinoma (A549), colorectal
adenocarcinoma (HT-29), and breast adenocarcinoma (MCF7).
For all three lines the EC50 values for ML10 were higher than the
highest concentration used (10 µM) conﬁrming a very high
selectivity window (>4500 fold) for this compound.
To investigate whether resistance is readily generated to this
class of inhibitor using prolonged exposure of parasites to sub-
lethal doses, we followed a published protocol26. No resistant
parasites were selected, suggesting that substitutions in the
compound-binding domain (or at a locus responsible for an
alternative resistance mechanism) are not readily selected under
these conditions. Drug resistant parasites were, however, readily
selected in control cultures treated with atovaquone, but test
cultures treated with the PKG inhibitor remained negative for the
duration of the experiment (Methods; Supplementary Fig. 10).
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Fig. 1 In vivo efﬁcacy of PKG inhibitors against rodent malaria parasites. a Groups of ﬁve female BALB/c mice were infected with 1x107/ml P. berghei
(ANKA) blood stage parasites in a Peters 4-day test and were given a twice daily dose (25 mg/kg) of one of three test compounds by oral gavage.
Chloroquine was used as a positive control at a single daily oral dose of 10 mg/kg. b Groups of ﬁve female BALB/c mice were infected with 1×107
P. chabaudi (AS) blood stage parasites and were given a single oral dose (50mg/kg) of either ML1 or ML4 by oral gavage just prior to the predicted onset
of schizogony. Chloroquine was used as a positive control at a single daily oral dose of 10mg/kg. c Groups of ﬁve BALB/c mice were infected with 1×107
P. chabaudi (AS) blood stage parasites and were given either a single or twice daily oral dose (50mg/kg) of ML10 by oral gavage. The ﬁrst dose was given
to both groups of mice just prior to the predicted onset of schizogony and in one group this was followed 3 h later when schizogony was predicted to have
been completed. The data are from single experiments each performed on a group of ﬁve mice. Error bars show the s.e.m
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Crystal structures give insight into the selectivity observed. To
seek insights into the interactions between Plasmodium PKG and
the new inhibitors, we expressed, puriﬁed and crystallized
recombinant protein samples from PfPKG and P. vivax PKG
(PvPKG), but only obtained diffracting crystals from the latter
with ML1 (PDB: 5FET) and ML10 (PDB: 5EZR). The two
orthologe are 92% identical in sequence over the full length
sequences. The kinase domains of the apo structures of the two
orthologe, when their atomic positions are aligned (Supplemen-
tary Fig. 11), deviate from each other by a negligible root-mean-
square distance (RMSD) of 0.3 Å. Clearly, PvPKG is a suitable
structural surrogate of PfPKG. We obtained high resolution co-
crystals of PvPKG with ML1 and ML10, respectively. The data
collected for the resulting co-structures (PDB: 5FET with ML1;
5EZR with ML10) showed clear electron density for each com-
pound. Alignment of their kinase domains with those from the
PvPKG apo structure (PDB: 5DYL) and a co-structure with
adenylyl imidodiphosphate (AMPPNP), a non-hydrolysable
analog of ATP (PDB: 5DZC) resulted in RMSD values lower
than 0.3 Å, showing that ligand binding changed the conforma-
tion of the protein negligibly (Supplementary Fig. 12). We also
note that all ligands formed complexes with the cGMP-free and
inactive state of PvPKG. To date, we have not succeeded in our
attempts to crystallize full length PKG from either Plasmodium
species with cGMP bound, with or without inhibitors or other
ligands in the catalytic domain. Comparison of the inhibitor-
bound structures reveals two key contributors to potency shared
by both compounds. First, hydrogen bonds between the amino-
pyrimidine and the backbone of V614 (V621 in PfPKG; Fig. 4a)
in both PvPKG structures form the quintessential hinge interac-
tion previously observed with many ATP-mimicking kinase
inhibitors. Second, the ﬂuorophenyl group occupies the hydro-
phobic pocket next to the relatively small gatekeeper (T611; T618
in PfPKG; Fig. 4b). The latter interaction also confers selectivity,
as this pocket would be blocked by the sidechain of a larger
gatekeeper residue, such as that found in the T618Q mutant and
the majority of S/T kinases (in both humans and parasites). The
pocket extends beyond the gatekeeper (Fig. 4b), with the addi-
tional cavity unexploited by ML1 but ﬁlled by the sulfonamide
group in ML10 engaging in hydrogen bonds with D675 (D682 in
PfPKG) and F676 (F683 in PfPKG) of the DFG triad (Fig. 4a).
Finally, both compounds engage in hydrophobic interactions with
a network of residues from both lobes and the hinge of the kinase
domain (Fig. 4c and Supplementary Fig. 13). Notably, the
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Fig. 2 Efﬁcacy of ML10 against P. falciparum in the GSK PfalcHuMouse model and determination of in vitro killing dynamics. a Two mice were treated with
vehicle and another two mice with either 50 or 100mg/kg of ML10 to test proof of concept of efﬁcacy in vivo. Parasitemia is shown over time in individual
mice during the efﬁcacy assay. The dotted horizontal line indicates 90% reduction in parasitaemia compared to vehicle-treated animals. Each symbol
represents an individual mouse. b Microscopic and ﬂow cytometric analysis of P. falciparum present in the peripheral blood of mice treated with vehicle or
ML10. Samples taken after one (48 h) and two cycles (96 h) of exposure to the test compound were further analyzed. Flow cytometry dot plots from
samples of peripheral blood show P. falciparum-infected human erythrocytes (blue rectangle). Images in the right-hand panels show Giemsa-stained blood
stage parasites. Blood ﬁlms from control untreated animals show normal staining and appearance. The parasites in ML10-treated animals show a relative
enrichment in late schizonts at Day 5, whereas most cells remaining in peripheral blood at Day 7 are pyknotic (red circle). Scale bar, 3 µm. c The in vitro
parasite reduction rate (PRR) assay was used to determine the onset of action and rate of killing as previously described24. P. falciparum was exposed to
ML10 at a concentration corresponding to 10× EC50. The number of viable parasites at each time point was determined as described24. Four independent
serial dilutions were tested with each sample to correct for experimental variation; error bars show the standard deviation. Previous results reported on
standard antimalarials tested at 10× EC50 using the same conditions are shown for comparison24
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methylation of the imidazopyridine core and the cyclopro-
pylmethylene extension from the aminopyrimidine in ML10
enhances this network and consequently increased the potency of
inhibition. Crystallography data collection and reﬁnement sta-
tistics are shown in Table 2.
Discussion
Currently there is optimism regarding several new chemical
entities undergoing clinical development as antimalarials27–32.
However, attrition rates in drug development across all ther-
apeutic areas are high. Although the use of protein kinase inhi-
bitors has been a successful strategy for treating a range of human
cancers for many years, with 25 approved drugs to date33, to our
knowledge it has not proved possible to exploit this target class to
treat infectious disease. An inhibitor of a P. falciparum lipid
kinase (PI4K) is showing real promise29 and is in clinical devel-
opment. Although our study has focused on the effects of the new
PKG inhibitors on blood stages and sexual stages, it has been
reported previously that PKG has roles in liver stages34 and
sporozoites18 and so it would be worth exploring the effects of the
new compounds on these additional stages to prevent the
initiation of a blood stage infection. Our results suggest that
ML10 or an analog with further optimized pharmacokinetic
properties, targeting the protein kinase PfPKG, might have sig-
niﬁcant efﬁcacy in terms of curing malaria in patients as well as
blocking transmission within the population in the context of
malaria elimination programmes35. Selectivity to avoid toxicity
and side effects is a major challenge in antimalarial chemother-
apy, especially when targeting protein kinases. However, our
results with the malaria parasite PKG with its small gatekeeper
residue conferring a rare structural feature, have demonstrated
that a highly selective inhibitor can be generated with sufﬁcient
potency to clear P. falciparum infection in vivo. Altogether our
results suggest that PKG inhibitors should be considered for
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Fig. 3 Transmission-blocking activity of ML10. P. falciparum (NF54)
gametocytes were incubated for 24 h with nine different concentrations of
ML10 and were each fed to a separate cage of 30–40 Anopheles stephensi
mosquitoes using a SMFA. Up to 20 surviving mosquitoes were dissected
on day 7 post-feed and oocyst numbers assessed by microscopy. This
experiment was performed twice and the ﬁgure shows the combined data
for oocyst intensity in each mosquito as a function of the compound
concentration for the replicate feeders. The left segment of the x-axis shows
the oocyst intensities in the vehicle (0.1% DMSO) controls. The positive
control was 10 μM dihydroartemisinin (DHA). Error bars show the s.e.m
ML1 ML10
V614V614 F676
D675
a
b
c
Fig. 4 Side-by-side comparison with key features in the PvPKG/ML1 and
PvPKG/ML10 co-structures. a Hydrogen bonds provide key interactions: At
the hinge of the kinase domain, V614 forms hydrogen bonds with the
amino-pyrimidine group of both ML1 (left) and ML10 (right). In addition,
ML10 extends a sulfonamide moiety to form hydrogen bonds with D675
and F676, resulting in signiﬁcantly greater inhibitory potency than ML1.
b Gatekeeper confers speciﬁcity: Both ML1 (left) and ML10 (right) extend a
ﬂuorophenyl group to occupy a hydrophobic pocket adjacent to T611
(magenta). This explains in part the speciﬁcity of the inhibitors as a residue
with a longer side-chain may potentially clash with this functional group.
c Hydrophobic network enhances inhibitory potency: Plasmodium PKG also
interacts with both ML1 (left) and ML10 using a network of hydrophobic
residues (see Supplementary Fig. 13 for the same ﬁgure with amino-acid
labels)
Table 2 Crystallography data collection and reﬁnement
statistics
PvPKG-ML1 PvPKG-ML10
PDB 5FET 5EZR
Data collection
Space group C2 C2
Cell dimensions
a, b, c (Å) 190.5, 117.2, 67.4 191.1, 118.0, 68.2
α, β, γ (°) 90.0, 94.3, 90.0 90.0, 95.2, 90.0
Resolution 45.00–3.07 (3.18) 50.00–2.50 (2.54)
Rsym 0.12 (0.85) 0.08 (0.68)
I/σI 15.3 (2.2) 19.2 (1.5)
Completeness (%) 99.4 (99.2) 97.7 (81.9)
Redundancy 4.2 (4.3) 4.1 (3.9)
Reﬁnement
Resolution (Å) 44–3.07 50–2.50
No. of reﬂections 28,885 50,525
Rwork/Rfree 0.23/0.25 0.23/0.26
No. of atoms
Protein 6235 6203
Compound 27 37
Water 62 69
Average B-factors 79.4 80.7
RMS deviations
Bond lengths (Å) 0.007 0.008
Bond angles (°) 0.80 1.19
Ramachandran plot
Favored regions 97.9 % 96.1 %
Allowed regions 100 % 99.9 %
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development as a component of a future antimalarial combina-
tion treatment.
Methods
Medicinal chemistry strategy summary. The chemistry program started with the
Merck imidazopyridine, Compound 2, here referred to as ML1 (signifying their
generation through a partnership between MRC Technology (now LifeArc) and the
London School of Hygiene and Tropical Medicine). Removing the dimethylben-
zylamine and attaching a basic amine to the aminopyrimidine via a phenyl spacer
(ML2) improved both cell potency and microsomal stability, but drastically
reduced permeability. Reintroduction of the dimethylamine (ML3) further
improved potency and restored permeability. A further boost to potency came with
the addition of a methyl (ML4) vicinal to the dimethylbenzylamine. Going back to
ML1, changing the 4-ﬂuorophenyl to 3-methylsulphonylphenyl (ML5) gave similar
potency and better microsomal stability to (ML1) but poorer permeability. Addi-
tion of a cyclopropylmethylene group to the aminopyrimidine (ML6) improved
both potency and permeability with a slight drop off in microsomal stability.
Moving to the 3-methylsulphonamidophenyl (ML7), both potency and perme-
ability were poorer than (ML1), though reintroduction of the 4-ﬂuoro group (ML8)
boosted potency but not permeability. Addition of the vicinal methyl (ML9) again
gave a slight improvement in potency and permeability and the addition of the
cyclopropylmethylene group (ML10) gave a compound with highly potent anti-
malarial activity. Analytical data are shown in Supplementary Note 1.
Expression and puriﬁcation of recombinant PKG. Full length PfPKG (NCBI
accession code XP_001348520) with native codon usage was cloned into the
pTrcHisC plasmid (Life Technologies) that includes an N-terminal His-tag as
described previously8. PfPKG with threonine 618 replaced with a glutamine
(PfPKG T618Q) was cloned into the same plasmid as described previously15.
Recombinant proteins were generated and puriﬁed using a protocol based on that
described previously8. Brieﬂy, freshly transformed E. coli RosettaTM 2(DE3) pLysS
(Novagen; Cat. No. 71403) were used for expression of recombinant PfPKG. 500 ml
cultures in LB Rich Broth (containing 50 μg/ml carbenicillin and 34 μg/ml chlor-
amphenicol) were grown in a shaking incubator at 37 °C until reaching an optical
density (O.D.) of 0.6–0.7. The temperature was reduced to 16 °C before induction
of expression with 1 mM IPTG. Incubation at 16 °C was continued overnight.
The cultures were harvested by centrifugation at 4000×g at 4 °C for 30 min, the
supernatant removed and the pellet stored at −80 °C for in excess of 1 h. The PKGs
were puriﬁed via the histidine tag on HiTrap TALON (cobalt) columns (GE
Healthcare) connected to an AKTA-FPLC as per the manufacturer's instruction.
Fractions were analyzed by SDS-PAGE and the main peak concentrated on 10 kDa
MWCO concentrators (Amicon). Puriﬁed proteins were stored in 50% glycerol at
−80 °C in single use aliquots. The ﬁnal buffer composition of the puriﬁed product
was: 50 mM Tris/HCl pH 7.5, 0.1 mM EGTA, 150 mM NaCl, 0.1%
β-mercaptoethanol, 50% glycerol, 0.03% Brij-35, 1 mM benzamidine and 0.2 mM
PMSF. PfPKG protein preparation was outsourced at the Division of Signal
Transduction Therapy, School of Life Sciences, University of Dundee.
Microﬂuidic assay for recombinant PfPKG. IC50 values were determined for test
compounds using a microﬂuidic mobility shift assay. Brieﬂy, compounds were
prepared over a 10-well ½ log dilution series in dimethyl sulfoxide (DMSO) in
duplicate in 50 μl volumes using 384-well polypropylene U-bottomed plates
(Thermo Scientiﬁc, UK). The plates contained positive/no inhibitor (DMSO only)
and negative (no enzyme) controls in columns 1, 2, and 23, 24. The reaction mix
for each well consisted of 20 µl of enzyme/peptide mix (1.25 nM PfPKG, 1.5 μM
FAM-labeled PKAtide [FAM-GRTGRRNSI-NH2, Cambridge Bioscience, UK] in
PfPKG assay buffer [25 mM HEPES (pH 7.4), 20 mM β-glycerophosphate, 2 mM
DTT, 10 µM cGMP, 0.01% (w/v) BSA, 0.01% (v/v) Triton X-100]) plus 5 µl of
compound. Samples were pre-incubated at room temperature for 30 min and
reactions were initiated by addition of 25 μl ATP mix (10 mM MgCl2 and ATP, at
KM of the enzyme under test [20 µM PfPKG and 90 µM PfPKG T618Q], in water).
Positive controls were complete reaction mixtures with 10% DMSO and negative
controls were reaction mixtures with 10% DMSO but lacking enzyme. Reactions
were allowed to proceed for 30 mins at room temperature, corresponding to
conversion of approximately 10% of the substrate in the DMSO controls. Reactions
were terminated by addition of 50 µl stop solution (25 mM EDTA in water).
Samples were analyzed by electrophoretic separation of substrate and product
peaks and ﬂuorescence detection using a Caliper Lab Chip EZ reader. (Perkin
Elmer, Waltham MA) with 0.2 s sip time, downstream voltage 500 V, upstream
voltage 1950 V and pressure 0.5 to 1.5 psi. Substrate and product peak heights were
measured and the ratio of the product peak height divided by the sum of the
product and substrate peaks were determined using EZ reader software (version
3.0.265.0) to obtain percentage conversion (P) values. P-values were normalized to
percentage activity relative to positive and negative controls were % activity=
100 × (P—Pneg ctrls)/(Ppos ctrls—Pneg ctrls) and ﬁtted to obtain IC50 values using a
4-parameter logistical ﬁt (XL-ﬁt, IDBS, Guildford UK). Liquid handling stages were
conducted on a Biomek robotic liquid handler (Beckman Coulter).
Plasmodium falciparum growth inhibition assays. We determined that a 72 h
P. falciparum (clone 3D7A; obtained from Lisa Ranford Cartwright, University of
Edinburgh) growth inhibition assay was necessary for full inhibition to manifest
itself and that this is due, most likely to a schizont-speciﬁc action rather than a
delayed death phenotype as observed for some antibiotic macrocycles. Hypox-
anthine incorporation assays36 were performed on P. falciparum asexual blood
stage parasites (wild-type 3D7 or T618Q gatekeeper mutant) to determine EC50
values for test compounds. Mixed staged parasites (primarily rings) were added to
96 well plates containing compounds at concentrations of 50 μM–0.3 nM. [3H]-
Hypoxanthine was added after 48 h to a ﬁnal concentration of 0.2 μCi. The
radioactivity of the labeled hypoxanthine incorporated into the parasite nucleic
acids over 24 h was determined relative to untreated controls using a Wallac 1450
Microbeta scintillation counter (Perkin-Elmer). Assays were carried out in tripli-
cate at least twice.
Peters 4-day test using the asynchronous P. berghei ANKA model. PKG
inhibitors were tested for in vivo efﬁcacy using randomized female BALB/c mice
(aged 6–8 weeks; Charles River Laboratories, Harlow, UK) infected intravenously
with 1x107/ml P. berghei (ANKA; from stocks held at LSHTM) blood stage
parasites in a standard 4-day test21. Animals in the test group were dosed once or
twice daily for 4 consecutive days beginning on the day of infection (i.e., D0 to D +
3) at 25 or 50 mg/kg via the oral route (po). Animals in control groups were dosed
once daily with chloroquine at 10 mg/kg/po or daily with pyrimethamine at 0.3 mg/
kg/po for 4 consecutive days. Reductions in blood stage parasitaemia were mea-
sured after 4 days' treatment.
Synchronous P. chabaudi model. Similar experiments were performed using
P. chabaudi AS (from David Walliker, University of Edinburgh) with the following
modiﬁcations. To allow dosing to be carried out more conveniently during the day,
reversal of the light/dark exposure of mice for 2 weeks prior to the experiment was
used to switch schizogony from midnight to noon each day. Mice were dosed at
different time points in an attempt to have maximal coverage at the point of
schizogony. All animal work protocols carried out at LSHTM were approved and
licensed by the United Kingdom Home Ofﬁce as governed by law under the
Animals (Scientiﬁc Procedures) Act of 1986, in strict accordance with the Code of
Practice Part 1 for the housing and care of animals (21 March 2005), available at
http://www.homeofﬁce.gov.uk/science-research/animal-research/
Efﬁcacy against P. falciparum in vivo. The efﬁcacy of ML10 against the P. fal-
ciparum 3D7 line was tested in the GSK P. falciparum humanized mouse model
(GSKPfalcHuMouse)22. The uncloned P. falciparum 3D7 line was kindly donated
by Drs. E. Dei-Cas and L. Delhaes from Institut Pasteur (Lille, France) and was
adapted to grow in peripheral blood of engrafted NODscid/β2 m−/− mice37. One
of the isolates obtained (Pf3D70087/N9) was expanded in vivo and established as a
reference strain for animal mouse model development.
Brieﬂy, age-matched (8–10-weeks old) female immunodeﬁcient NOD-scid IL-
2Rγc-null mice (The Jackson Laboratory, Bar Harbor, ME) were engrafted with
human erythrocytes (Red Cross Transfusion Blood Bank in Madrid, Spain) by
intraperitoneal daily injection with 1 ml of a 50% hematocrit erythrocyte
suspension (RPMI 1640 medium, 25% (vol/vol) decomplemented human serum,
3.1 mM hypoxanthine) throughout the experiment. The mice were infected with
2 × 107 P. falciparum Pf3D70087/N9-infected erythrocytes (Day 0) at ~ 40%
chimerism in peripheral blood. The drug treatment was given to mice on Day 3
after infection every 12 h for 4 consecutive days by oral gavage in a volume of
administration of 10 ml/kg bodyweight, at a dose of 50 or 100 mg/kg bodyweight.
ML10 was prepared in 90% ddH2O, 7% Tween 80, 3% ethanol. Parasitemia was
measured by ﬂow cytometry in samples of peripheral blood stained with the
ﬂuorescent nucleic acid dye SYTO-16 (Molecular Probes, Cat. No.: S-7578) at a
concentration of 5 µM and anti-murine erythrocyte TER119 monoclonal antibody
(10 µg/ml; Beckton Dickinson) in serial 2 μL blood samples taken every 24 h until
assay completion as described22. AUCED90 is the average daily exposure of the
compound in whole blood that reduces parasitemia at day 7 of the in vivo assay by
90% with respect to parasitemia in vehicle-treated mice.
The plasma levels of ML10 in mice from the efﬁcacy experiment were measured
in serial samples of peripheral blood (25 μl) taken by tail puncture at 0.25, 0.5, 2, 4,
6, and 12 h after the ﬁrst administration. The blood samples were immediately
lysed by mixing with 25 μl of distilled water, frozen on dry ice and stored at −80 °C
until analysis. The compounds were extracted from 10 μl of each lysate by
liquid–liquid extraction in the MultiScreen Solvinert 0.45 μm Hydrophobic PTFE
96- well plate system (Millipore) and stored frozen at −80 °C until analysis by LC/
MS/MS in API4000 (AB Sciex, Framingham, MA). The compound concentration
vs. time data were analyzed by non-compartmental analysis using Phoenix®
Version 6.3 (Pharsight Corporation, Mountain View, CA, USA). Additional
statistical analysis was performed with GraphPad Prism® Version 6.02 (GraphPad
Software Inc, San Diego CA, USA).
All the experiments were approved by the DDW Ethical Committee on Animal
Research, performed at the DDW Laboratory Animal Science facilities accredited
by AAALAC, and conducted in accordance with European Directive 86/609/EEC
and the GSK Policy on the Care, Welfare and Treatment of Animals. The human
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biological samples were sourced ethically and their research use was in accord with
the terms of the informed consent. Erythrocyte concentrates from malaria-negative
donors were provided by Biobancos de Castilla y Leon, Barcelona and Centro de
Transfusiones de Madrid and the Red Cross Transfusion Blood Bank in Madrid,
Spain. Research was conducted according to POL-GSKF-410 and was in accord
with the terms of the informed consent of each donor.
In vitro parasite reduction ratio. In vitro PRR testing was conducted at Glax-
oSmithKline (Tres Cantos, Madrid, Spain) as previously described24. The assay
used the limiting dilution technique to quantify the number of parasites that
remained viable after drug treatment. P. falciparum strain 3D7A (Malaria Research
and Reference Reagent Resource Center (MR4), BEI Resources; Cat. No. MRA-
102) was treated with a drug concentration corresponding to 10× IC50. Conditions
of parasites exposed to treatment were identical to those used at GSK in the IC50
determination (2% hematocrit, 0.5% parasitemia). Parasites were treated for 120 h.
Drug in culture medium was renewed daily over the entire treatment period.
Parasite samples were collected from the treated culture every 24 h (24, 48, 72, 96,
and 120 h time points); drug was washed out of the sample, and parasites were
cultured drug-free in 96-well plates by adding fresh erythrocytes and culture
medium. To quantify the number of viable parasites after treatment, threefold
serial dilutions were used with the above-mentioned samples after removing the
drug. Four independent serial dilutions were performed with each sample to cor-
rect experimental variations. The number of viable parasites was determined after
21 and 28 days by counting the number of wells with growth using [3H]-hypox-
anthine incorporation. The number of viable parasites was back-calculated by using
the formula Xn-1 where n is the number of wells able to render growth and X the
dilution factor (when n= 0, number of viable parasites is estimated as zero).
In vitro selection of resistant parasites. The resistance proﬁling was carried out
according to the assay protocol described previously26, which looks for the emer-
gence of resistant mutants against a compound concentration of 3× IC50. P. fal-
ciparum lab isolate Dd2 (from stocks held at LSHTM) was used for this experiment
and the control compound used was atovaquone. Parasites were plated in triplicate
at 109 parasites/well and maintained until parasites were observed microscopically
(using Giemsa-stained blood ﬁlms) or until Day 60 whichever was the soonest.
Parasites from the atovaquone plate were discarded at Day 18 and cultures treated
with the PKG inhibitor ML1 were parasite negative at Day 60. Gametocytes were
present initially but were absent from Day 11.
Standard membrane feeding assays. Mature P. falciparum (NF54) gametocytes
(14 day culture, 0.3–0.5% gametocytes, 2% haematocrit) were obtained from an
automated tipper system and incubated with compound for 24 h as previously
described38. Anopheles stephensi (Sind-Kasur Nijmegen strain39 were reared at 30 °
C and 70–80% humidity, while exposed to a 12/12 h day/night cycle. On the day of
feeding, the gametocyte culture was adjusted to 50% hematocrit with human red
blood cells and human serum and fed to 3–5 day old mosquitoes using a glass
membrane mini-feeder system containing 0.35 ml of the P. falciparum culture/
compound mix40. Unfed and partially fed mosquitoes were removed after feeding
and blood fed females were maintained at 26 °C and 70–80% humidity. Up to
20 surviving mosquitoes were collected on day 7 post-infection and oocysts were
visualized using a 1% merchurochrome solution and quantiﬁed by microscopy.
IC50 values were determined by logistic regression using Maximum Likelihood
Estimation to ﬁnd best ﬁt41.
Gametogenesis assays. Plasmodium falciparum clone 3D7A (obtained from Dr
Lisa Ranford-Cartwright, University of Edinburgh) gametocytes were initiated and
cultured using an adapted version of the traditional Trager and Jenson method
modiﬁed by Fivelman and colleagues42. Stage V gametocytes were puriﬁed on a
60% Percoll gradient. Puriﬁed parasite samples were diluted in warm complete
media (RPMI-1640 (Sigma), 0.5% Albumax (Invitrogen), 0.03% L-glutamine
(Sigma), 0.2% Glucose (Sigma), 1× hypoxanthine (Sigma)), to a volume that would
allow a ﬁnal volume of 100 µM per sample and a haematocrit of <10%. Test
compounds were added to 1.5 ml tubes and 100 µl of parasite suspension added to
give a ﬁnal concentration of 30 µM xanthurenic acid, 2 µM ML1, and 1 µM ML10.
Control tubes containing DMSO only were kept at 37 °C. All other samples were
incubated at room temperature for 30 min immediately after addition of test
compounds. Samples were then washed once in warm RPMI followed by removal
of the supernatant to leave a ﬁnal haematocrit of roughly 50%. Samples were
smeared on glass slides and ﬁxed in 100% methanol (VWR) then stained for 15
min in 10% Giemsa R66 (VWR) and observed by light microscopy. The number of
gametocytes at stage V and rounded up per 900 erythrocytes were counted three
consecutive times to produce an average count. Numbers of parasites rounded up
were compared to the no drug control.
Cytotoxicity assays with human cell lines. A549 (lung carcinoma; ATCC, Ref.
ATCC® CCL-185™), plated at 7.5×103 cells/well; HT-29 (colorectal adenocarci-
noma; ATCC, Ref. ATCC® HTB-38™), plated at 7.5×103 cells/well; and MCF7
(breast adenocarcinoma; ATCC, Ref. ATCC® HTB-22™), plated at 9× 103 cells/well,
were placed into clear bottom, opaque 96 well plates in cell line-speciﬁc medium
and allowed to attach overnight. Cells were incubated with nine concentrations of
ML10 (0.001–10 µM in 0.1% DMSO) and grown in MEM Eagle medium (MEM-
EBSS with Non-Essential Amino Acids w/o L-Glutamine; Lonza BE12-662F), 10%
[v/v] FCS, 1× GlutaMAX™ Supplement (Life Technologies, 35050061) and 50 units/
ml penicillin and 50 µg/ml streptomycin for 48 h. Six independent assays were
performed for each line and were carried out by CXR Biosciences Ltd. End point
for cytotoxicity assessment was carried out using an ATP depletion kit (CellTiter-
Glo Luminescent Cell Viability Assay for ATP quantitation (Promega, Cat #
G7572)). Results expressed relative to the 0.1% DMSO control. Unpaired Student’s
t-tests were performed using GraphPad Prism software (7.0).
Crystallography. For crystallography, recombinant PvPKG was expressed and
puriﬁed using a previously described baculovirus system43. Crystals were obtained
by setting up protein samples in sitting drop vapor diffusion experiments at 18 °C.
For ML1, the following crystallization conditions were used: 10% PEG 5000 MME,
5% tacsimate, 0.1 M HEPES pH 7.0, 15 mM spermidine, and 25% glycerol. The
crystallization conditions for ML10 were: 15.5% PEG 3350, 0.1 M HEPES pH 7, 0.1
M succinate pH 7.0. For both, data were collected at beam line 19ID of Argonne
National Laboratory’s Advanced Photon Source (http://www.sbc.anl.gov/index.
html) and processed using HKL-300044 (Table 2). The PvPKG-ML1 co-structure
was solved using Phaser for molecular replacement and the previously deposited
PvPKG-apo coordinates (PDB code: 5DYL) as a search model. Reﬁnement was
carried out using the Buster reﬁnement software (version 2.10.0. developed by
Bricogne et al., 2011 Cambridge, UK: Global Phasing Ltd. and REFMAC45 com-
bined with iterative manual model building using the molecular graphics program
Coot46 to a ﬁnal R factor of 21.9 %. The PvPKG-ML10 co-structure was deter-
mined by reﬁning the PvPKG apo structure (PDB code 5DYL) against the data
acquired from the isomorphous complex crystals. The structure was reﬁned using
REFMAC45 to a ﬁnal R factors of 22.5%. The geometry of the ﬁnal models was
checked using MolProbity47 for reasonable clash scores and no ramachandran
outliers. Crystallographic details and reﬁnement statistics are summarized in
Table 2. The coordinates have been deposited in the Protein Data Bank with the
PDB codes 5FET (ML1) and 5EZR (ML10). Stereo images of electron density maps
for the compounds are shown in Supplementary Fig. 14.
Data availability. Data corresponding to crystal structures presented can be found
at the RCSB Protein Data Bank (http://www.rcsb.org/pdb/home/home.do) with the
following codes:
PvPKG apo: 5DYL, PvPKG with ML1: 5FET, PvPKG with ML10: 5EZR. All
relevant data are available from the authors upon request.
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